Pasireotide

Trade Name: 
Signifor
Manufacturer/Distributor: 
Novartis Pharmaceuticals
www.novartis.ca
514-631-6775
Classification: 
Synthetic analogue of somatostatin
ATC Class: 
H01CB05 - pasireotide
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2013/09/23
Date Marketed in Canada (yyyy/mm/dd): 
2013/11/26
Presentation: 
Injection: 0.3 mg/mL. DIN: 02413299
Injection: 0.6 mg/mL. DIN: 02413302
Injection: 0.9 mg/mL. DIN: 02413310
Comments: 
Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed, as long as clinical benefit is derived.